Clinical Trials Logo

Clinical Trial Summary

This is a Phase II, single-arm study to evaluate the efficacy, safety, and PK of oral linperlisib (YY-20394) monotherapy in adult patients with R/R Peripheral T/NK Cell Lymphoma. The study will be conducted at approximately 15 sites in United States.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05274997
Study type Interventional
Source Shanghai YingLi Pharmaceutical Co. Ltd.
Contact Meiyue Hong
Phone +862151370693
Email myhong@yl-pharma.com
Status Recruiting
Phase Phase 2
Start date May 1, 2022
Completion date December 1, 2023